Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort

Paksoy et al. (2026) used multigene panel testing in 647 BRCA1/2-negative Turkish patients, with Genomize-SEQ supporting variant analysis. They identified clinically relevant non-BRCA variants in 16.2% of cases, led by CHEK2, ATM, and TP53.